Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pagoda: PDS with Ranibizumab in Diabetic Macular Edema
NCT04108156Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2019
- Primary completion
- Jul 2027
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in diabetic macular edema (DME), sponsored by Roche. Started Sep 2019; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04108156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108156.